Beauty Industry Acquisitions Shift From Scale to Focus
Beauty industry acquisitions are no longer only about getting bigger; they now centre on reshaping portfolios through selective takeovers, asset sales and funding rounds that sharpen brand focus, unlock capital and support targeted growth in core categories. As mega-mergers stall, the industry is moving toward makeup brand consolidation, mid-market roll-ups and balance-sheet-driven divestitures that change who owns growth brands and how they are backed. The Estée Lauder Puig deal that never closed, Waldencast’s sale of Obagi Medical, and Proya’s controlling stake in Flower Knows all show groups redirecting resources to the brands and categories they believe can win. At the same time, smaller labels like Violette_FR tap growth capital, confirming that money is still flowing into the sector even as the largest players grow more cautious on price and structure.
Inside the Estée Lauder–Puig Talks and a Moving Mega-Deal Chessboard
The Estée Lauder Puig deal collapsed over valuation, underlining how price discipline now shapes beauty portfolio strategy at the top end. Stephane de La Faverie said Estée Lauder walked away because the combination would not deliver “growth and the profitability at the right price point.” Marc Puig, meanwhile, stressed that Puig “is not for sale” and that any merger required alignment on governance, business leadership and economic terms. Before Estée Lauder entered the picture, Puig disclosed that Kering had approached it about a long-term beauty licensing tie-up in exchange for a minority stake and cash, but those talks also ended without a transaction. Kering later turned to a strategic partnership with L’Oréal, highlighting how beauty industry acquisitions and alliances are constantly being reconfigured among a small circle of powerful platforms, each defending control while seeking scale in fragrance, skincare and colour.
Waldencast’s Obagi Medical Sale: From Platform Dream to Single-Brand Bet
Waldencast’s decision to sell Obagi Medical to Bridgepoint for USD 460 million (approx. RM2,116 million) marks a sharp pivot from its original platform vision to a focused bet on Milk Makeup. Created as a SPAC and later acquiring Obagi Medical and Milk Makeup in a transaction valued at USD 1.2 billion (approx. RM5,520 million), Waldencast once aimed to build a multi-brand beauty and wellness house. After a strategic review announced in August 2025, the board concluded that divesting professional-focused Obagi Medical, along with Novaestiq and earlier Obagi Japan trademark rights sold for USD 82.5 million (approx. RM380 million), would best strengthen its balance sheet. When the deal closes, the company plans to repay its outstanding senior term loan facility and concentrate investment on Milk Makeup, where leadership continuity and clearer category focus are expected to support future growth.
Proya and Flower Knows: Mid-Market Makeup Brand Consolidation
While some giants scale back, Proya is expanding through targeted makeup brand consolidation. The company has lifted its indirect stake in Flower Knows to 51% by acquiring an additional 12.6% from shareholder Yang Zifeng for CNY351 million, turning the label into a consolidated subsidiary. Flower Knows generated CNY1.7 billion in revenue and CNY280 million in net profit last year, becoming Proya’s second-largest cosmetics brand and a key growth engine as its core skincare business slows. The deal fits Proya’s multi-brand, multi-category strategy and strengthens its position in colour cosmetics alongside Timage and Insbaha, which have been delivering strong growth. This type of mid-market acquisition shows how beauty industry acquisitions are not only about global mega-deals: regional champions are also building scaled portfolios by absorbing fast-growing makeup brands that already display strong demand and distinct positioning.
Funding the Next Wave: From Strategic Reviews to Series B Rounds
Even as mega-deals prove volatile, capital continues to flow into promising beauty brands, keeping the innovation pipeline active. The sale of established assets like Obagi Medical and potential divestitures reportedly under review at The Estée Lauder Companies, including brands such as Too Faced, Smashbox and Dr. Jart+, suggest that large groups are pruning to free resources and reduce complexity. At the same time, early and growth-stage labels, exemplified by makeup player Violette_FR and its recent USD 5 million (approx. RM23 million) Series B round, are attracting targeted investment to scale product development, marketing and distribution. Together, these moves show a split-screen market: conglomerates refine beauty portfolio strategy through disposals and selective additions, while investors and founders back the next generation of niche, story-rich brands that may one day become acquisition targets themselves.